Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:KRYSNYSE:OGNNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$32.43-0.9%$34.40$29.31▼$61.38$3.91B0.591.56 million shs2.41 million shsKRYSKrystal Biotech$132.46+0.3%$143.35$122.80▼$219.34$3.82B0.65303,983 shs691,210 shsOGNOrganon & Co.$9.77-1.2%$9.88$8.01▼$23.10$2.57B0.583.46 million shs4.77 million shsSPRYARS Pharmaceuticals$15.80-0.7%$14.37$7.55▼$18.51$1.56B0.841.31 million shs1.34 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-0.92%-5.67%+3.58%-28.62%-37.56%KRYSKrystal Biotech+0.28%-3.36%+4.56%-29.22%-23.43%OGNOrganon & Co.-1.22%-2.59%+15.59%-36.30%-52.01%SPRYARS Pharmaceuticals-0.69%+2.66%+11.11%+27.83%+95.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.2187 of 5 stars4.53.00.04.61.50.80.0KRYSKrystal Biotech4.3982 of 5 stars3.51.00.04.72.12.51.9OGNOrganon & Co.4.686 of 5 stars3.32.01.73.71.73.32.5SPRYARS Pharmaceuticals3.2143 of 5 stars3.62.00.00.02.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.93Moderate Buy$70.92118.70% UpsideKRYSKrystal Biotech 3.00Buy$211.1359.39% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0084.33% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0096.20% UpsideCurrent Analyst Ratings BreakdownLatest SPRY, CYTK, KRYS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/7/2025CYTKCytokineticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M209.70N/AN/A($1.15) per share-28.20KRYSKrystal Biotech$290.52M13.18$4.65 per share28.48$32.90 per share4.03OGNOrganon & Co.$6.40B0.40$4.86 per share2.01$1.83 per share5.34SPRYARS Pharmaceuticals$89.15M17.41$0.01 per share1,878.77$2.64 per share5.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1631.8413.14N/A37.17%14.64%13.28%8/4/2025 (Estimated)OGNOrganon & Co.$864M$2.883.392.611.0311.92%227.43%7.34%8/5/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest SPRY, CYTK, KRYS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.82%N/A2.78%N/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ALatest SPRY, CYTK, KRYS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A5.995.99KRYSKrystal BiotechN/A9.659.27OGNOrganon & Co.16.491.671.15SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%OGNOrganon & Co.77.43%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%KRYSKrystal Biotech13.70%OGNOrganon & Co.1.96%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.43 million116.20 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableSPRY, CYTK, KRYS, and OGN HeadlinesRecent News About These CompaniesEric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJune 20 at 9:17 PM | marketbeat.com249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource CouncilJune 20 at 7:36 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from BrokeragesJune 19 at 1:47 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comJim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”June 15, 2025 | msn.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?June 13, 2025 | marketbeat.comCantor Fitzgerald Predicts SPRY FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates SPRY FY2026 EarningsJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 6, 2025 | marketbeat.comBank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 5, 2025 | marketbeat.comAmeriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 3, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's WhyMay 31, 2025 | marketbeat.comARS Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comMillennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 26, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to SellMay 24, 2025 | marketbeat.comWoodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 24, 2025 | marketbeat.comNorthern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from AnalystsMay 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 SharesMay 23, 2025 | insidertrades.comRafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 23, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LPMay 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRY, CYTK, KRYS, and OGN Company DescriptionsCytokinetics NASDAQ:CYTK$32.43 -0.30 (-0.92%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$32.28 -0.15 (-0.46%) As of 06/20/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$132.46 +0.37 (+0.28%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$132.52 +0.06 (+0.05%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Organon & Co. NYSE:OGN$9.76 -0.12 (-1.16%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$9.76 -0.01 (-0.10%) As of 06/20/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.ARS Pharmaceuticals NASDAQ:SPRY$15.80 -0.11 (-0.69%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$15.76 -0.04 (-0.25%) As of 06/20/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
